FOCUSED ON WOMEN'S HEALTH and hormone-sensitive cancer for healthy aging worldwide

Discover our research

Our solution

A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.

Find out about Intrarosa™

Our goal as a Quebec company

 

Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.

Research and Development

Latest News

Read the news

Lupin Pharma Canada Announces Partnership with Endoceutics for the Commercialization of INTRAROSA®

March 8, 2021

Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize INTRAROSA® in Canada.

ENDOCEUTICS ANNOUNCES ACQUISITION OF THE INTRAROSA® U.S. COMMERCIAL RIGHTS BY MILLICENT PHARMA

May 27, 2020

Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.

ENDOCEUTICS RECEIVES HEALTH CANADA APPROVAL FOR INTRAROSA

November 6, 2019

Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.